For instance, the administration of Trastuzumab (a monoclonal antibody targeting the extracellular domain of HER2) to standard adjuvant chemotherapy has improved both the DFS and OS of HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.